Where to buy Vepotolizumab (POLIVY)

Vepotolizumab (POLIVY), sold under the trade name Polivy, was developed by Roche's Genentech subsidiary and is a U.S. Food and Drug Administration (FDA)-approved treatment for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). These patients had received at least 2 previous treatments, and it was combined with two other cancer treatments, such as bendamustine and rituximab. Vepotuzumab is a type of drug called an antibody-drug conjugate (ADC). The drug is designed to be different from traditional chemotherapy because of its ability to find dividing B cells, including those that become cancerous. Almost all B cells (including cancer cells) have a marker called CD79b on their surface, which works by using the CD79b marker to find and attach to B cells.

The patent drug Vepotuzumab has also been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. It is an injectable preparation. The price of 30 mg per box may be around 10,000 yuan. The price of the Hong Kong version of 140 mg per box may be around 60,000 yuan (the price may fluctuate due to exchange rates). This drug is a strictly controlled drug, and its purchase may be difficult. The price of the European version of vepotuzumab available overseas, Specifications per box of 140 mg, may be around RMB 90,000 (the price may fluctuate due to the exchange rate). The domestic original drug has basically the same ingredients as the foreign original drug and is expensive. There is currently no generic version of vepotuzumab on the market.